TY - JOUR
T1 - Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment
AU - Hoshide, Satoshi
AU - Yano, Yuichiro
AU - Shimizu, Motohiro
AU - Eguchi, Kazuo
AU - Ishikawa, Joji
AU - Kario, Kazuomi
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/8
Y1 - 2012/8
N2 - It is unknown whether home blood pressure (BP) variability reduction is associated with target organ damage (TOD) protection independently of home mean BP reduction. We enrolled 310 hypertensive patients whose systolic BP (SBP) at home was over 135mmHg. The subjects measured their BP in the morning and evening for 7 days. In addition, we measured urinary albumin excretion (UAE) as a marker of TOD before and after 6 months of candesartan treatment (+thiazidediuretics). At baseline, UAE was associated with average home SBP (r=0.24, P<0.001), the s.d. of home SBP (r=0.15, P=0.011), and the maximum home SBP (r=0.27, P<0.001). During the intervention, significant reductions were found in average home SBP (146±13 vs. 132±12mmHg, P<0.001), s.d. of home SBP (12.9±4.8 vs. 11.8±4.4mmHg, P<0.001), and maximum home SBP (172.5±18.0 vs. 155.9±17.5mmHg, P<0.001). UAE levels were significantly reduced after 6months of therapy compared with baseline (18.9 vs. 12.1 mgg-1 Cre, P<0.001). In multiple regression analysis, the treatment-induced reduction in UAE was significantly associated with that of average home BP (P=0.003) but was not associated with that of s.d. of home SBP or that of maximum home SBP. Home BP variability is not itself an interventional target beyond lowering mean home BP during anti-hypertensive treatment.
AB - It is unknown whether home blood pressure (BP) variability reduction is associated with target organ damage (TOD) protection independently of home mean BP reduction. We enrolled 310 hypertensive patients whose systolic BP (SBP) at home was over 135mmHg. The subjects measured their BP in the morning and evening for 7 days. In addition, we measured urinary albumin excretion (UAE) as a marker of TOD before and after 6 months of candesartan treatment (+thiazidediuretics). At baseline, UAE was associated with average home SBP (r=0.24, P<0.001), the s.d. of home SBP (r=0.15, P=0.011), and the maximum home SBP (r=0.27, P<0.001). During the intervention, significant reductions were found in average home SBP (146±13 vs. 132±12mmHg, P<0.001), s.d. of home SBP (12.9±4.8 vs. 11.8±4.4mmHg, P<0.001), and maximum home SBP (172.5±18.0 vs. 155.9±17.5mmHg, P<0.001). UAE levels were significantly reduced after 6months of therapy compared with baseline (18.9 vs. 12.1 mgg-1 Cre, P<0.001). In multiple regression analysis, the treatment-induced reduction in UAE was significantly associated with that of average home BP (P=0.003) but was not associated with that of s.d. of home SBP or that of maximum home SBP. Home BP variability is not itself an interventional target beyond lowering mean home BP during anti-hypertensive treatment.
UR - http://www.scopus.com/inward/record.url?scp=84864656838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864656838&partnerID=8YFLogxK
U2 - 10.1038/hr.2012.46
DO - 10.1038/hr.2012.46
M3 - Article
C2 - 22476230
AN - SCOPUS:84864656838
SN - 0916-9636
VL - 35
SP - 862
EP - 866
JO - Hypertension Research
JF - Hypertension Research
IS - 8
ER -